

Predictor Role of Systemic Inflammation in Ovarian Cancer

Seda Keskin¹([ID](#)), Duygu Altin¹([ID](#))

¹Obstetrics and Gynecology Department, Medical Faculty, Ordu University, Ordu, Turkey

Copyright@Author(s) - Available online at <https://dergipark.org.tr/en/pub/mbsjohs>
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License,



Received: 17 August 2021, Accepted: 26 August 2021, Published online: 31 August 2021
© Ordu University Institute of Health Sciences, Turkey, 2021

Abstract

Objective: The study aims to investigate the diagnostic value of hemogram derived systemic inflammation parameters in ovarian cancer.

Methods: Totally, the study group consisted of 60 patients with suspected ovarian masses who underwent surgery between February 1th, 2020, and May 1th, 2021, in Ordu University Training and Research Hospital. The patients included in the study were divided into two groups according to postoperative histopathological diagnosis, benign group (consisting of 39 patients) and malign group (consisting of 21 patients). The analysis of the receiver operating characteristic (ROC) curve was used to discover the optimal cut-off values of the hemogram derived blood parameters to predict ovarian cancer.

Results: In the cancer group; 85% of the patients were diagnosed with epithelial ovarian cancer and 62% at late stage. As compares with benign ovarian mass group, the ovarian cancer group had higher neutrophil counts (6.67+3.17 vs 4.64+1.94) (p=0.006), but lower lymphocyte counts (1.60+0.68 vs 2.22+0.64) (p=0.003). The high NLR values (cut-off 2.557) predict ovarian cancer with 71.4% sensitivity and 69.2% specificity (AUC 0.817, p=0.000, CI=0.712-0.922). The high dNLR values (cut- off 1.881) also predict cancer with similar sensitivity and specificity as NLR (AUC 0.814, p=0.000, CI 0.708-0.921). Significant cut-off values for the other hemogram derived parameters were 0.26, 0.0165, 159.66 and 770.611 for MLR, NPR, PLR and SII, respectively. Additionally, the high values of CA 125 (cut-off 34.45) and CA 15-3 (cut-off 16.4) was founded to be related with ovarian cancer.

Conclusions: This paper revealed that high inflammatory parameters such as NLR and dNLR in patients with ovarian masses are mainly associated with ovarian cancer. In the study, it was emphasized that simple and easily accessible hemogram parameters should be used in addition to tumor biomarkers such as CA 125, CA 15-3, which are routinely used in predicting ovarian cancers. We think that more valuable results will be achieved with comprehensive studies designed prospectively.

Key words: Neutrophil-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio, systemic inflammation, ovarian cancer.

Suggested Citation: Keskin S, Altin D. Predictor role of systemic inflammation in ovarian cancer Mid Blac Sea Journal of Health Sci, 2021; 7(2):282-288

Address for correspondence/reprints:

E-mail: adesniksek@gmail.com

Seda Keskin

Telephone number: +90 (505) 627 34 12

Introduction

Ovarian cancer is a fairly common malignancy among women. Although, its frequency varies between countries, it ranks third after cervical cancer and uterine corpus cancer. Additionally, ovarian cancer is the most common cause of gynecological cancer-related deaths due to its high incidence and high mortality rate (1). The fact that ovarian cancer is generally asymptomatic at an early stage, and the limited number of sensitive and specific diagnostic markers cause more than two-thirds of the patients to be diagnosed at an advanced stage. Although treatments such as staging or debulking surgery and chemotherapy continue to evolve over the years, the five-year survival rate remains under 30%, due to early metastasis and late diagnosis (2).

Although tumor biomarkers such as CA125 (cancer antigen 125), CA15-3 (cancer antigen 15-3), CA19-9 (cancer antigen 19-9), CEA (carcino embryonic antigen) and AFP (alfa fetoprotein), which have been used for many years, are in the first place in diagnosis, many other markers have been investigated for early diagnosis of ovarian cancer and to predict prognosis. But which marker should be used is still a matter of debate. Therefore, finding effective markers and using them together with conventional tumor biomarkers is very important in the diagnosis and treatment of ovarian cancer, which is a serious public health problem (3).

Emerging evidence revealed that up to 20% of the cancers were caused by chronic inflammation, and systemic inflammatory response played a key role in the initiation, invasion, progression and distant metastasis of malignancies. Numerous markers of inflammatory-immune response have been proposed as potential prognostic factors for cancer. Among these inflammation markers hemogram derived ratios such as NLR and dNLR are routinely tested and widely used in clinical practice (4-6).

A newly identified marker, dNLR, calculated using the formula for neutrophil count/non-neutrophil white blood cell count, has been widely investigated to predict prognosis in many types of cancer, including breast, urological, digestive cancers and malignant melanoma (4,5,7,8). However, the diagnostic value of these inflammatory parameters in gynecological (especially ovarian) cancers remains unclear. In the current study, we aimed to reveal the clinical importance of inflammatory parameters in ovarian cancer and to investigate the success in predicting malignancy in ovarian masses.

Methods

This retrospective, single-center study was conducted between February 1st, 2020, and May 1th, 2021, in Ordu University Training and Research Hospital. The study was approved by the ethics committee of Ordu University Medical Faculty.

We retrospectively analyzed 96 patients with suspected ovarian mass who underwent surgery. Non-confirmed PCR negative cases, even if they were symptomatic or with a history of contact, were excluded from the study. Pregnancy, age < 18 years, acute inflammation, blood disease and smokers were excluded from cohort. 11 covid-19 suspected/positive, 18 smokers, 4 tubo-ovarian abscess/pelvic infections, 2 blood diseases, 1 pregnant patient were excluded from the study. As a result, a cohort was formed with 60 patients who met the study criteria.

Patients with ovarian masses included in the study were divided into two groups according to their postoperative histopathological diagnosis. Thence, there was benign group (consisting of 39 patients) and malign group (consisting of 21 patients).

As a routine protocol, hemogram and tumor biomarkers (Ca 125, Ca 15-3, Ca 19-9, CEA, AFP) tests were applied to each patient for preoperative evaluation. Blood samples were taken from all patients upon admission before any treatment began. Primary objective of the study is whether hematological parameters and some inflammatory indices derived from hematological parameters may be used in ovarian cancer patients pre-operatively as simple screening.

Hematologic indices, hematologic ratios and tumor biomarkers were presented in Table 1. These hematological indices were calculated as NLR, which is the ratio between the count of neutrophils ($\times 10^9$ cells/L) and the count of lymphocytes ($\times 10^9$ cells/L), dNLR is neutrophils/(white blood cells-neutrophils), PLR is the ratio between the count of platelets ($\times 10^{11}$ cells/L) and the count of lymphocytes ($\times 10^9$ cells/L) and the SII is defined as the counts of neutrophils ($\times 10^9$ cells/L) multiplied by the counts of platelets ($\times 10^{11}$ cells/L) and divided by the count of lymphocytes ($\times 10^9$ cells/L), NPR is the ratio between the count of neutrophils ($\times 10^9$ cells/L) and the count of platelets ($\times 10^{11}$ cells/L).

Statistical analysis

For analyzing the results of the study, IBM SPSS version 20 (SPSS Inc., Chicago, IL, USA) program was used. Analyzes were carried out in a 95% ($p=0.05$) confidence interval. Because the study period is short and so study population is limited and

retrospective design of the study, sample size is not calculated. Descriptive statistical methods and comparative statistics had been used in the study. Descriptive data derived from the study were presented as mean \pm standard deviation. The normality distribution of numerical variables was studied with the Kolmogorov-Smirnov and the Shapiro-Wilks tests. The independent samples t-test was used for numerical variables with normal distribution and Mann-Whitney U test was used for those which not distributed normally. The analysis of the receiver operating characteristic (ROC) curve was used to discover the optimal cut-off values of the hemogram derived blood parameters to predict ovarian cancer. AUC was interpreted as excellent if 0.9-AUC-1, good if 0.8-AUC-0.9, moderate if 0.7-AUC-0.8, poor if 0.6-AUC-0.7, and failed if 0.5-AUC-0.6.

Results

Totally, sixty women who were operated for an ovarian mass were included in the retrospective, cohort study. Twenty-one had pathologically confirmed ovarian cancer and thirty-nine were diagnosed benign ovarian cysts.

The demographic and clinical characteristics are presented in Table 1. The age range of patients was 18-80 years. Although the mean age was lower in the benign group (42.03 \pm 13.6), no statistically significant difference was observed with the mean age of the malignant group (49.1 \pm 13.6) ($p=0.661$). Additionally, there was no significant difference in body mass indexes between the groups (23.6 \pm 4.4 vs 22.7 \pm 3.4) ($p=0.342$).

In the cancer group, eighteen women (85.75) had epithelial ovarian cancer, while three patients had a non-epithelial tumor subtype. FIGO (International Federation of Gynecology and Obstetrics) staging was performed in cases with ovarian cancer. FIGO stages were as follows; 1- six patients, 2- two patients, 3- eleven patients, 4- 2 patients. Approximately 62% of patients had advanced (stage 3-4) ovarian cancer.

The hematologic and tumor biomarkers of the study group are presented in Table 2. As compares with benign ovarian mass group, the ovarian cancer group had significantly higher neutrophil counts (6.67 \pm 3.17 vs 4.64 \pm 1.94) ($p=0.006$), but lower lymphocyte counts (1.60 \pm 0.68 vs 2.22 \pm 0.64) ($p=0.003$). Accordingly, we found that many hemogram derived parameters, especially NLR (neutrophil-to-lymphocyte ratio) and dNLR (derived neutrophil-to-lymphocyte ratio), increased due to systemic inflammation in the ovarian cancer group. In addition, we found statistically significantly higher

tumor biomarkers CA 125 and CA 15-3 in the ovarian cancer group. On the other hand, no significant difference between the groups in terms of CA 19-9, CEA and AFP values was detected.

ROC curves were made to compare the diagnostic utility of tumor biomarkers (CA 125, CA 15-3, CA 19-9, CEA, AFP) and hemogram derived ratios (NLR, dNLR, MLR, PLR, NPR, SII) in diagnosing ovarian cancer. ROC graphics and Area Under the Curve (AUC) values are presented in Figure 1 and Table 3.




Figure 1. ROC graphics

We found that the high NLR and dNLR had an impact in ovarian cancer. The high NLR values (cut-off 2.557) predict ovarian cancer with 71.4% sensitivity and 69.2% specificity (AUC 0.817, $p=0.000$, CI=0.712-0.922). The high dNLR values (cut-off 1.881) also predict cancer with similar sensitivity and specificity as NLR (AUC 0.814, $p=0.000$, CI 0.708-0.921). Significant cut-off values for the other hemogram derived parameters were 0.26, 0.0165, 159.66 and 770.611 for MLR, NPR, PLR and SII, respectively. Additionally, the high values of CA 125 (cut-off 34.45) and CA 15-3 (cut-off 16.4) was founded to be related with ovarian cancer.

Table 1. The demographic and clinical characteristics of the study group

Characteristics	Ovarian cancer (n=21)	Benign ovarian masses (n=39)	P value
Age	49.10±13.68	42.03±13.03	0.661
BMI	23.6±4.4	22.7±3.4	0.342
Tumor subtype			
Epithelial	18		
Non-epithelial	3		
FIGO stage			
I	6		
II	2		
III	11		
IV	2		

Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics

Table 2. Hematologic and tumor biomarkers of the study group **

Biomarker	Ovarian cancer (n=21)	Benign ovarian masses (n=39)	P value
WBC	9.08±3.26	7.62±2.41	0.140
HB	11.95±1.67	11.96±1.55	0.843
NEU	6.77±3.17	4.64±1.94	0.006*
LYM	1.60±0.68	2.22±0.64	0.003*
MONO	0.54±0.21	0.53±0.16	0.798
EOS	0.11±0.09	0.20±0.26	0.158
BASO	0.034±0.022	0.031±0.020	0.721
MCV	85.22±6.82	84.14±7.40	0.369
MCH	27.32±2.66	27.12±3.02	0.969
MCHC	32.02±1.06	32.17±1.53	0.090
PCT	0.28±0.04	0.30±0.08	0.309
PDW	11.10±2.24	10.67±1.94	0.721
RDW	44.78±7.90	41.69±9.62	0.117
PLT	287.47±55.97	310.48±84.82	0.120
NLR	5.81±6.22	2.19±1.06	0.000*
dNLR	3.75±3.58	1.58±0.64	0.000*
MLR	0.37±0.18	0.25±0.10	0.003*
PLR	226.44±159.35	148.18±52.58	0.008*
NPR	0.024±0.015	0.015±0.006	0.005*
MPVPR	0.035±0.009	0.034±0.012	0.281
LYM*PLT	474.02±283.50	705.34±303.79	0.003*
RDWPR	0.16±0.04	0.014±0.05	0.072
SII	1646.38±1728.93	710.90±503.99	0.000*
CA 125	295.06±408.20	37.11±66.12	0.000*
CA 15-3	41.43±40.68	12.68±6.09	0.000*
CA 19-9	971.89±4359.99	15.21±27.35	0.138
CEA	8.45±21.3	1.80±2.05	0.055
AFP	11.42±44.36	1.84±1.21	0.710

Abbreviations: WBC, white blood cell; HB, hemoglobin; NEU, neutrophil; LYM, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO, basophil; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PCT, platelet; PDW, platelet distribution width; RDW, red cell distribution width; PLT, platelet; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NPR, neutrophil-to-platelet ratio; MPVPR, mean platelet volume-to-platelet ratio; LYM*PLT, lymphocyte*platelet; RDWPR, red cell distribution width-to-platelet ratio; SII, systemic immune inflammation index; CA 125, cancer antigen 125; Ca 15-3, cancer antigen 15-3; CA 19-9, cancer antigen 19-9; CEA, carcino embryonic antigen; AFP, alfa feto protein

*statically significant

**values are given as mean ± standard deviation

Table 3: Area Under the Curve (AUC) values

Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval		Cut off value	Sensitivity	Specificity
				Lower Bound	Upper Bound			
Hemogram derived ratios								
NLR	.817	.054	.000*	.712	.922	2.557	71.2	69.2
dNLR	.814	.054	.000*	.708	.921	1.881	71.4	71.8
MLR	.732	.068	.003*	.598	.866	0.26	66.7	61.5
NPR	.720	.070	.005*	.582	.858	0.016	66	62
PLR	.709	.068	.008*	.576	.842	159.6	61.9	69.2
SII	.794	.057	.000*	.681	.906	770.6	76.2	76.9
Tumor biomarkers								
CA 125	.789	.067	.000*	.657	.921	37.4	71.4	74.4
CA 15-3	.817	.064	.000*	.693	.942	17.4	76.2	74.4

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

*Statically significant

Discussion

The systemic inflammatory response plays a significant role in tumor development and progression. Although the genetic predisposition in the development of cancer cannot be denied, many studies have shown that inflammation caused DNA damage and excessive production of cytokines (including IL-2, IL-6, TNF- α and VEGF) triggered the initiation and progression of cancer. In addition, it has been determined that inflammation inhibits the apoptosis of DNA damaged cells and increases angiogenesis that helps growth of tumor tissue (9-11).

Although some studies were conflicting, recent evidence showed that systemic inflammatory response markers such as NLR, dNLR, MLR, NPR, PLR and SII were associated with prognosis of various cancer. In a meta-analysis of 6585 patients published in 2019 investigating urological cancers, high dNLR values were associated with decreased cancer-specific survival in renal cell carcinoma, prostate cancer, and urothelial cancers (8). In a study investigating the clinical outcome of patients diagnosed with metastatic gallbladder cancer, it was shown that dNLR and CEA values predict a better prognosis when used together (12).

In a meta-analysis report investigating poor prognosis in 10599 breast cancer patients, high dNLR value was found to be associated with poorer overall and recurrence-free survival (7). In another breast cancer study, NLR, dNLR, PLR values were found to be associated with both disease-specific and disease-free survival. Especially in patients with breast cancer with high PLR values, more lymph node metastases were detected (6). Furthermore, the relationship between dNLR and cancer survival has been demonstrated in many cancers such as malignant melanoma and digestive cancers (4,5).

In the literature, studies investigating hematological parameters and gynecological cancers are insufficient. In a study investigating cervical cancer prognosis, NLR, dNLR, and PLR were associated with lymph node metastasis, recurrence-free and overall survival (13). In a meta-analysis of data from 3390 patients diagnosed with endometrial cancer, high pretreatment NLR and PLR values were founded to be associated with poor prognosis (14). In two studies examining lymph node metastasis in endometrial cancer, it was shown that hemogram parameters predict lymph node metastasis (15,16). In three other endometrial cancer studies, hemogram parameters showing systemic inflammation were shown to be associated with cancer stage, overall

survival, and lymphovascular-myometrial-cervical invasion (17-19).

In studies on ovarian cancer, it has been shown that high NLR and dNLR values worsen the prognosis and can be used together with tumor biomarkers such as CA 125 to predict ovarian cancer (20-22).

In our study, the hemogram derived parameters (NLR, dNLR, MLR, NPR, PLR, LYM*PLT and SII) revealing systemic inflammation in the ovarian cancer group was significantly higher. Although tumor biomarkers (especially CA 125) are in widespread use, their low sensitivity and specificity has always been a problem. In the current study we also found that CA 125 and CA 15-3 predicted ovarian cancer with an average sensitivity and specificity of 70-76%. Therefore, we think that the use of NLR and dNLR ratio and tumor biomarkers together will be more useful in predicting ovarian cancer.

The limitations of the study were the retrospective design and small cohort of the study. In the future, there is a need for studies with larger patient numbers in which the subtypes of benign ovarian masses are also examined in detail. Being a single center study and evaluation of the patients by the same team overall period are other advantages of the study. On the other hand, examining many hemogram and hemogram derived parameters together with tumor biomarkers is the main factor that strengthens our study.

Conclusion

Today, the importance of systemic inflammation in cancer development is frequently studied. In support of this, we found the hemogram derived parameters (NLR, dNLR, MLR, NPR, PLR, LYM*PLT and SII) in the ovarian cancer group was significantly higher than in the benign ovarian mass.

In the study, it was emphasized that simple and easily accessible hemogram parameters should be used in addition to tumor biomarkers such as CA 125, CA 15-3, which are routinely used in predicting ovarian cancers. We think that more valuable results will be achieved with comprehensive studies designed prospectively.

Ethics Committee Approval: This study was conducted with the approval of the ethics committee of Ordu University Faculty of Medicine, Non-Invasive Clinical Research Ethics Committee. (Ethics Committee date and Decision no: 12.08.2021/2021/186)

Peer-review: Externally peer-reviewed.

Author Contributions:

Idea, Design, Audit, Data Collection and/or Processing, Analysis and/or Interpretation: Writing, S.K, D.A

Conflict of Interest: The authors certify that they have no financial or non-financial interest in the subject matter or materials discussed in this manuscript.

Financial Disclosure: The author declared that this study hasn't received no financial support.

References

1. Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: International Agency for Research on Cancer. World Health Organization. ISBN (PDF) 978-92-832-0448-0
2. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet.* 2015;131(2):111-22.
3. Wang HP, Wu HY, Wang Y, Wang L. Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology. *J Biol Regul Homeost Agents.* 2017;31(3):691-5.
4. Liu F, Luo H, Zhu Z, Zhu P, Huang J. Prognostic significance of peripheral blood-derived neutrophil/lymphocyte ratio in patients with digestive cancer. *J Cell Physiol.* 2019;234(12):22775-86.
5. Afzal MZ, Sarwar T, Shirai K. Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. *J Immunother.* 2019;42(7):251-64.
6. Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. *PLoS One.* 2018;26;13(7):e0200936.
7. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. *Medicine (Baltimore).* 2018;97(49):e13340.
8. Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis. *Int J Surg.* 2019;72:146-53.
9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell.* 2010;19;140(6):883-99.
10. Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumor development. *Trends Cell Biol.* 2015;25(4):214-20.
11. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. *Br J Cancer.* 2004;90(11):2053-8.
12. Du JH, Lu J. Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient. *J Clin Lab Anal.* 2019;33(2):e22684.
13. Chen L, Zhang F, Sheng XG, Zhang SQ, Chen YT, Liu BW. Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte. *Medicine (Baltimore).* 2016;95(32):e4381.
14. Ni L, Tao J, Xu J, Yuan X, Long Y, Yu N, et al. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis. *Arch Gynecol Obstet.* 2020;301(1):251-61.
15. Kadan Y, Calvino AS, Katz A, Katz S, Moore RG. Predictors for lymph nodes involvement in low risk endometrial cancer. *J Obstet Gynaecol.* 2017;37(4):514-8.
16. Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients. *Oncology.* 2019;96(5):259-67.
17. Temur I, Kucukgoz Gulec U, Paydas S, Guzel AB, Sucu M, Vardar MA. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. *Eur J Obstet Gynecol Reprod Biol.* 2018;226:25-9.
18. Bacanakgil BH, Kaban I, Unal F, Guven R, Sahin E, Yildirim SG. Predictive Value of Hematological Inflammatory Markers in Endometrial Neoplasia. *Asian Pac J Cancer Prev.* 2018;25;19(6):1529-32.

19. Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. *BMC Cancer*. 2020;24;20(1):464.
20. Wu YY, Qin YY, Qin JQ, Zhang X, Lin FQ. Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. *J Clin Lab Anal*. 2019;33(4):e22833.
21. Chen L, Wang X, Shu J, Xu S, Wu Q, Yu Y. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis. *Int J Gynaecol Obstet*. 2019;147(2):212-8.
22. Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. *Arch Gynecol Obstet*. 2018;297(4):849-57.